Astellas Pharma Inc. (TYO: 4503) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of PADCEV (enfortumab vedotin) in combination with Keytruda (pembrolizumab) as neoadjuvant treatment before surgery, continued as adjuvant treatment after radical cystectomy, for adults with resectable muscle‑invasive bladder cancer (MIBC) in the European Union (EU).
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | CHMP of the European Medicines Agency (EMA) |
| Opinion Type | Positive opinion recommending approval |
| Regimen | PADCEV (enfortumab vedotin) + Keytruda (pembrolizumab) |
| Indication | Resectable muscle‑invasive bladder cancer (MIBC) in adults – perioperative use |
| Treatment Setting | Neoadjuvant (before surgery), continued as adjuvant (after radical cystectomy) |
| Opinion Date | 18 Sep 2026 |
| Next Steps | European Commission final decision, typically issued within approximately two months of a CHMP positive opinion |
Drug Profile & Mechanism of Action
- Molecule: Enfortumab vedotin, a first‑in‑class antibody‑drug conjugate (ADC) targeting Nectin‑4, a cell‑surface protein highly expressed in bladder cancer.
- Mechanism: Per nonclinical data, the ADC binds to Nectin‑4‑expressing cells, is internalized, and releases the antitumor payload monomethyl auristatin E (MMAE) inside the cell, resulting in cell cycle arrest and programmed cell death (apoptosis).
- Combination Partner: Keytruda (pembrolizumab), an anti‑PD‑1 immunotherapy, pairing a tumor‑directed ADC with immune checkpoint blockade.
- Treatment Innovation: Moves the established combination upstream into the perioperative (curative‑intent) setting, rather than the advanced/metastatic disease for which it is already approved.
Clinical & Regulatory Footprint
| Region | Approved Indication | Setting |
|---|---|---|
| United States, Japan, several other countries/regions | Locally advanced or metastatic urothelial cancer (la/mUC) in adults, regardless of cisplatin eligibility | Advanced/metastatic |
| European Union (existing) | Unresectable or metastatic urothelial cancer in adults eligible for platinum‑containing chemotherapy | Advanced/metastatic |
| European Union (recommended) | Resectable MIBC in adults – neoadjuvant + adjuvant perioperative therapy | Curative‑intent perioperative |
Specific trial names, endpoints, and efficacy data underpinning the perioperative CHMP opinion were Not disclosed in the announcement.
Market Impact & Outlook
- Earlier‑Line Expansion: Extending PADCEV + Keytruda into resectable MIBC shifts the franchise from palliative to curative‑intent treatment, opening a substantially larger patient pool – surgery‑eligible MIBC patients who currently receive predominantly cisplatin‑based neoadjuvant chemotherapy.
- EU Label Advantage: While the existing EU combination label is limited to platinum‑eligible patients, the recommended perioperative indication targets the resectable MIBC population, potentially decoupling uptake from cisplatin‑eligibility constraints in this setting.
- Combination Franchise Synergy: The approval pathway deepens the global footprint of the ADC–immunotherapy pairing already marketed across the US, Japan, and multiple other regions, reinforcing PADCEV’s position in Astellas’ oncology portfolio.
- Competitive Landscape: Perioperative MIBC is an intensifying battleground for ADC and checkpoint‑inhibitor developers; an EU authorization would position this combination among the first targeted perioperative options in the region.
- Commercial Timeline: Pricing, reimbursement, and launch timing following the expected European Commission decision were Not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the regulatory timeline, final European Commission decision, clinical outcomes, and commercial expectations for PADCEV (enfortumab vedotin) in combination with Keytruda (pembrolizumab). Actual results may differ materially due to risks including final authorization conditions, market adoption, competitive dynamics, and pricing and reimbursement negotiations. A CHMP positive opinion does not constitute a marketing authorization until the European Commission issues its final decision.-Fineline Info & Tech
